Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary

November 17, 2026

London Stock Exchange GB Health Care Biotechnology earnings 39 min

Earnings Call Speaker Segments

Carl Spana

executive
#1

Good morning, everyone, and thank you for joining us for Palatin's call covering the fiscal first quarter of 2027. I'm Dr. Carl Spana, President and CEO of Palatin. Joining me today is Steve Wills, who serves as Palatin's Chief Financial Officer and Chief Operating Officer. Steve is going to start things off with an update on the financial and corporate side. Steve?

Steve Wills

executive
#2

Thanks, Carl, and good morning to all of you. I'll walk through the financial results we posted for the first quarter of fiscal 2027, which closed on September 30, 2026, talk about the operating priorities we're focused on, and share some perspective on our financial strategy as we approach key clinical development milestones. Through the quarter, we kept concentrating our resources on moving our next-generation MC4R programs forward, especially the IND-enabling work for our lead lipidated peptide and the development of our oral small molecule candidates. Our view is that these investments put Palatin in position for a significant stretch of clinical development that begins in calendar year 2027. On the fiscal first quarter results for the 3 months that ended September 30, 2026, Palatin recognized roughly $362,000 in collaboration and license revenue, versus approximately $8.8 million in the comparable period a year earlier. Revenue in the current quarter came from research and development services carried out under our collaboration with Boehringer Ingelheim. The prior year period benefited from substantial upfront milestone payments tied to that agreement, and that explains the difference between the two years. Now on expenses. Research and development came in at approximately $3.4 million, compared with approximately $2.5 million in the comparable prior year period. Notably, spending tied directly to our MC4R obesity development programs rose by approximately $2.1 million, versus approximately $1 million in the prior year period. That increase reflects our continued progress on IND-enabling studies and related development activities for our long-acting peptide program, along with lead candidate optimization work for our oral small molecule program. In our view, these expenditures are important investments in moving our development candidates toward clinical evaluation. General and administrative expenses were approximately $2.1 million, compared with approximately $1.7 million in the comparable prior year period. That increase came mainly from higher stock-based compensation expense and professional fees; for the fiscal first quarter, we reported a net loss of approximately $5.1 million, or $1.29 per basic and diluted common share. Turning to Palatin's cash position and financial strategy. Net cash used in operating activities was approximately $3.7 million during the quarter, compared with approximately $1.6 million in the prior year period. As of September 30, 2026, we held approximately $3.7 million in cash and cash equivalents. We recognize that taking our development programs through the next stages of clinical development will call for additional capital. We are assessing financing alternatives, including public and private equity transactions, while we keep pursuing strategic collaborations and other opportunities to support our programs. Our financing strategy aims at securing the capital needed to carry out our development plans and reach the milestones that we believe can create substantial value for Palatin and its shareholders. We have successfully accessed the capital markets and executed strategic transactions throughout Palatin's history, and we remain focused on pursuing the financial resources required to advance our programs. At the same time, we continue to manage operating expenditures carefully and to prioritize investment in our highest value development opportunities. On the strategic partnership and operating priority side, one key part of what we're doing is using the wider melanocortin portfolio to open up further value opportunities via licensing and collaboration deals. Through our partnership with Boehringer Ingelheim and the licensing arrangement with Altanispac Labs, we have chances for future economic participation, and at the same time we can keep our internal resources focused on the MC4R obesity programs. We're also still assessing strategic opportunities for the rest of our development assets across the MC1R landscape. As we look forward, our operating priorities haven't changed. First, move our lead lipidated MC4R peptide candidate through the IND-enabling and manufacturing work required so we can start a Phase I clinical study in the first half of calendar year 2027. Second, take our oral small molecule MC4R program forward to candidate selection, IND-enabling development and a planned clinical start in the second half of calendar 2027. Third, keep broadening the opportunities inside our MC4R portfolio, which includes our non-lipidated peptide series and our oral peptide approach; and fourth, lock in the financial and strategic resources needed to back these objectives. To close, Palatin is entering a significant period in its development. Our strategic direction is firmly in place, our next-generation MC4R programs are moving ahead, and our research and development investments are increasingly focused on programs that could offer meaningful clinical and commercial differentiation. We believe Palatin has the scientific expertise, proprietary compounds and development capabilities to compete effectively in this emerging market. We stay confident about what our programs can achieve and committed to moving them through the next important stages of development. With that, I'll hand the call back to Carl. Carl?

Carl Spana

executive
#3

Thank you, Steve. What I'd like to do today is concentrate on the considerable opportunity we believe exists for Palatin through our next-generation therapies that target the melanocortin 4 receptor. Also, on the headway we're making throughout our development programs and the key milestones that lie in front of us. The treatment picture for rare neuroendocrine obesity disorders keeps changing quickly. Crucially, agonism at the melanocortin 4 receptor, or MCR4 receptor, has by now been validated both clinically and commercially as a therapeutic approach for patients with certain rare obesity disorders that are driven by dysfunctions in the melanocortin pathway. That validation matters a great deal. It's now clear that turning on the MCR4 receptor can yield real clinical gains in illnesses that have long been notoriously difficult to manage. That creates considerable room for innovative, differentiated MCR4 therapeutics, and Palatin is aimed squarely at that space. We intend to build next-generation MCR4 agonists capable of delivering strong efficacy, much better tolerability, little to no hyperpigmentation, and dosing schedules that work in practice for patients who might require treatment for their entire lives. We apply our deep expertise in melanocortin receptor pharmacology, peptide engineering and drug development toward creating therapies meant to overcome the shortcomings of products already on the market and those still emerging. Receptor selectivity stands out as one key distinguishing feature of our development programs. Appetite control, food consumption, and energy balance are chiefly governed by the melanocortin 4 receptor. In contrast, skin pigmentation involves the melanocortin 1 receptor. Skin darkening or hyperpigmentation may result from activating the melanocortin 1 receptor, and this has become a hurdle when creating MCR4 agonist drugs. Reducing that effect matters for patients with these conditions, since they need treatment for life. What we aim to do is turn on the melanocortin 4 receptor selectively and steer clear of MCR1 activity. We've tested compounds from both of our next-generation peptide series, and they've demonstrated strong melanocortin 4 receptor agonist activity while not functioning as agonists at the melanocortin 1 receptor. We view that as a significant accomplishment, and it reinforces what we're aiming for: cutting MCR1 mediated hyperpigmentation substantially, with the possibility of eliminating it entirely. What we want is to create MCR4 therapeutics that deliver clinically meaningful efficacy without asking patients to tolerate adverse effects that aren't necessary and that stem from off-target receptor activation. In our view, that will be an important point of differentiation. Now, on our lead program: we're continuing to advance our lipidated long-acting melanocortin 4 receptor selective peptide toward clinical development, and we keep making progress. Our lead candidate comes from the CL2000 peptide series. In studies done in mice undergoing dialysis before human trials, this candidate showed notable decreases in how much the animals ate and in their body weight after a single weekly subcutaneous dose. Also important, pharmacokinetic results from bigger animals back up the possibility of dosing people once a week or even less often; these features sit at the heart of how we are approaching development. When it comes to individuals living with long-term, lifelong conditions like hypophenobesity, CreatiWillie syndrome and BardeVital syndrome, a treatment offering strong efficacy alongside convenient dosing and tolerability that has been approved might mean, or does mean, meaningful steps forward for the field. Through our lipidated peptide approach, we seek to extend the amount of time the drug remains in the body and the duration of its pharmacological action, which may make it possible to provide sustained therapeutic advantages with fewer injections. At present we are moving forward the IND-enabling preclinical work and manufacturing activities required to support our first-in-human study; our goal is to launch a Phase I single multiple — and multiple ascending dose study during the first half of calendar 2027, with initial clinical data targeted for the second half of that year; this marks an important forthcoming milestone for Palatin. That study is going to assess safety, tolerability, pharmacokinetics and pharmacodynamic characteristics of our next-generation lipidated peptide in humans and will additionally include measurements of skin pigmentation, body weight, body mass index and effects on appetite. We think that combining melanocortin 4 receptor activity with sustained activity demonstrated preclinical efficacy makes this a particularly promising development candidate. We're continuing to push forward our non-lipidated TL1000 Peppa series as well, and that includes formulation approaches designed to enable long-acting dosing. All of these programs together provide us with several shots at creating differentiated peptide-based melanocortin 4 receptor therapies. In addition to our injectable peptide work, we see considerable opportunity in melanocortin 4 receptor therapies. For patients and caregivers dealing with chronic conditions, oral administration is clearly appealing. We think our deep background in medical chemistry and pharmacology gives us a solid basis for addressing the difficulties that tripped up earlier oral melanocortin 4 receptor programs. Our next-generation molecule program draws on what we learned from PL-7737, our previous development candidate, as well as from our wider melanocortin 4 receptor discovery work. We've now found compounds that are more potent and more selective for MCR4 than earlier candidates, and they also show favorable orbit availability and preclinical results. We continue to refine these candidates, focusing especially on potency, receptor selectivity, cash intestinal tolerability, and how suitable they are for chronic dosing. Our goal is to advance a chosen candidate into IND-enabling development during the first half of 2027 and to start a Phase I clinical study in the second half of calendar 2027. Beyond that, our oral peptide agonist program has advanced considerably. We've created selective melanocortin 4 receptor agonists that have gastrointestinal stability and oral bioavailability sufficient to support further development. Even though this work sits at an earlier stage, it presents a strong chance to create innovative MCR4 peptide drugs given by mouth, and it broadens the technologies and therapeutic profiles available for us to explore. Rather than depending on one molecule or one delivery method, we aim to assemble a portfolio of best-in-class monocot receptor therapies. Growing interest surrounds novel therapeutics based on non-comp receptors, and com holds a very strong position to capitalize on that interest and bring best-in-class therapeutics forward. To begin with, we possess deep expertise in the melanocortin receptor system, which includes developing bremelanotide — the first melanocortin 4 receptor compound to win FDA approval. Second, we've built up a considerable store of proprietary knowledge in medicinal chemistry, pharmacology and clot development, and that body of work guides how we design our next-generation compounds. Third, our development strategy zeroes in on particular clinical shortcomings that have emerged with therapies already on the market and those still coming along. And fourth, we're pursuing multiple complementary routes simultaneously — lipidated injectable peptides, non-lipidated peptide formulations, oral small molecules and oral peptide approaches, for instance. In our view, these capabilities leave us well placed to create highly differentiated therapies in a market where the therapeutic mechanism is already well validated and where a meaningful unmet medical need persists. In addition to our internal noninformed receptor development programs, we continue to extract value from our Boehringer Ingelheim portfolio. Our partnership with Boehringer Ingelheim in retinal diseases provides ongoing reimbursement for research, along with the possibility of further payments tied to development, regulatory and commercial milestones, as well as royalties. The agreement with Altanispac Labs shifts responsibility for future development of PL-9643 and dry eye disease to that partner, while Palatin retains potential future economic benefits. In addition, we continue to assess opportunities to partner our remaining clinical-stage and proof-of-concept programs. These kinds of arrangements form a key part of our broader strategy: we keep our proprietary emphasis on developing melanocortin 4 receptor therapies for obesity, while relying on collaborations and licensing to move other assets forward. Before we open it up for questions, one last thing I'd like to stress: in our view, the melanocortin 4 receptor system stands among the strongest validated mechanisms available for addressing rare neuroendocrine obesity disorders. What lies ahead is the chance to create improved medicines built on that mechanism. That is precisely what our next-generation programs are engineered to accomplish. We've shown persuasive preclinical attributes — including strong monocot receptor agonism with no melanocortin 4 receptor innovation in the compounds tested, along with lasting activity from our lead lipidated peptide. These programs are moving toward unclinical evaluation, and we have key milestones planned across 2027; with that, I'll hand the call over for questions.

Scott Henry

analyst
#4

Let me begin with the broad view. There's been substantial interest in the MC4R pathway and in peptides. Of course, there are reports of interest in Rhythm Pharmaceuticals from AstraZeneca. We also have Gilead and PepStar. What do you think this activity tells us about the pathway? I mean, it really does look like interest is intensifying. And where do you see Palatin sitting in this landscape?

Carl Spana

executive
#5

Thanks, Scott. I think it's obvious, isn't it — it demonstrates that interest in this mechanism keeps growing, both on the peptide side and on the small molecule side. We're getting far more inbound interest. Many more companies are reaching out to us. So we're pretty excited about where the mechanism stands, with rising interest not only from specialty pharma but from big pharma too, as AstraZeneca shows; broadly speaking, peptides are becoming much more compelling because of the ability to limit them to increase — to cut down on injections, meaning going from one or several shots a day to a single shot each week or even longer; and the fact that a lot of these liberated peptides can be stabilized for oral delivery is genuinely opening up the field. So big pharma is, once again, taking another look at peptides as a validated therapeutic approach. And all of this rests on the success that's been observed with the GLP-1s; so on the whole, I see a very significant positive for the melanocortin field and for peptides generally. That's the interest AstraZenica is demonstrating in the target. So — and from Palatin's standpoint, I believe we're positioned very well; we were a peptide company; we've developed plenty of peptides as antagonists; we hold many core technologies for knowing how to lipidate these peptides properly so they keep their selectivity, need fewer injections, and retain good potency; and now we've been opening — we've essentially been able to open up the possibility of oral delivery for these peptides too. We've managed to produce both lipidated and non-lipidated versions that are extremely stable in gastrointestinal fluid and in intestinal fluid as well, and they're demonstrating oral bioavailability in the range that permits them to be 1 oral delivery. So we feel we're positioned really well on every front.

Scott Henry

analyst
#6

Okay. To add to that point — if investors are treating Rhythm as a comparable for Palatin, how would you compare your work with what Rhythm is doing?

Carl Spana

executive
#7

Rhythm has achieved a great deal in leading the way with MCR4 agonists for rare and orphan indications. That really broadens the field, and as I mentioned on the call, the focus now is on securing the strongest compounds. The key is creating improved peptide or small molecule drugs that enter that market and deliver superior and distinct benefits for patients. When it comes to peptides, we think a lipidated strategy outperforms the use of polymers. Polymer pouches are effective, though they come with drawbacks—unlike the data peptides. You can draw a direct parallel to the GLP-1 story. Those began as injections taken once or twice daily, then moved to polymers, and afterward to lipidation; lipidated drugs have truly taken off. They're simply easier to use, the formulary is easier to work with, you can titrate, and there's far more flexibility. So our belief is that an eliminated peptide which lowers MCR1 activity while keeping MCR4 potency high will genuinely be a better product than the other peptide options available; on the small molecule side. The aim here is—there's one out there. Sure. First-gen. The compounds we're developing — and ones others might be developing — should be better when it comes to selectivity, potency, and overall drug-like properties, which will let them be given in a simpler form and across a broader dose range, potentially producing greater efficacy. So all around, we're quite differentiated from Rhythm's work. That said, they exist, they're first, they're pioneering these markets, and we aim to arrive with better, differentiated products and compete. And I believe we're there with the compounds we're advancing.

Scott Henry

analyst
#8

All right, great. Maybe I'll hand things over to Steve for a moment. Steve, with all the extra attention on the sector right now, does that leave you feeling a lot more confident? I realize financing is a significant need. It doesn't seem as though the warrants will be kicking in just yet. So would you say this backdrop improves the near-term picture for raising money?

Steve Wills

executive
#9

For sure. To start, thank you for posing that question, Scott. The — we truly need to acknowledge how important it is to bring in added capital that supports the coming phases of our development programs. And that really is the — even with the progress on the MCR4 obesity program, that remains our central priority. We've been operating for over 25 years. We've been 100% successful when it comes to tapping the capital markets, and also in carrying out strategic transactions. And that has happened across numerous development cycles and market environments. As Carl pointed out, we hold a compelling portfolio of next-generation MC4R programs that we believe stand apart from, even so, the commercial programs that exist and the development, the programs currently in development; we, naturally, are actively assessing financing alternatives, public, private equity, and we're reviewing strategic opportunities in that area. It's — interest has been considerably stronger during the last several months than it has ever been at Palatin, and the MCR4 landscape is the main driver of that. But because Nostradamus hasn't called me back, we can't give assurances about the timing or the terms of any transaction, though we're focused on moving the programs forward and securing the resources needed to reach our objectives.

Scott Henry

analyst
#10

All right, great. Just a few small follow-up questions for you, Carl. First, regarding the peptide side, you have PL1000, which is the non-lipidated one, and PL2000, the lipidated one. From what I understand, between those two compounds, PL2000, the lipidated version, is ahead. And it looks like that's the one you'll bring into the clinic first. Is that right?

Carl Spana

executive
#11

That's right. That's right. Again, we have both of what we call simple peptides, which are basically our psyched peptides that are very true — they look like melanotide, they would look like in setmelanotide, these would be the other injectable type of product; and they have to be formulated — formulated polymers or other kinds of technologies if you wanted the extended delivery. So we're moving ahead with the lipidata. The lipidated, we believe, is a better product and a better approach for delivering peptides over the long term.

Scott Henry

analyst
#12

All right, and then one more thing I wanted to ask about was the oral small molecule compound — it looks as though that timeline has moved up somewhat, with data now anticipated during the first half of '28. Is that right? Or was I simply being cautious by expecting it in the second half of '28?

Steve Wills

executive
#13

Let me take the timeline question, Scott. This is Steve. No — that hasn't changed on our end. Both the oral small molecule program and the oral peptide program are running roughly 2 quarters behind the lipidated peptide program. So given the first half target for the lipidated peptide to begin Phase I and have data by the end of the second half of 2027, you can just flip that around for the Orsman molecule and/or the oral peptide, which should be starting in the second half of '27 with data in the first half of calendar 2028.

Joe Pantginis

analyst
#14

Josh here, filling in for Joe, and I had a few questions about the Obesity Week data. You showed some good selectivity for MCR4 over MC1R, so I'm curious what you think about that with respect to hyperpigmentation, and how confident you are that it will translate into patients?

Carl Spana

executive
#15

Sure. The aim is to eliminate as much activity as we can so hypopigmentation can be avoided. When treating these conditions we're discussing, these sorts of chronic conditions, treatment lasts a lifetime. So the best profile is one that lets patients stay on therapy the longest, and hyperpigmentation can be a side effect tied to one activity that a number of patients may not particularly want to experience. That's why having the high degree of activity we have matters. And again, when we discuss selectivity, there are a couple of ways to look at it, and I don't want to get too technical, but the most important way we think about it is really lowering how active your compounds are against the receptor. That's a little bit different from what others are doing. So we're fairly confident we achieved that — we have achieved it. As we head into the clinic, we do expect to see reduced pigmentation or none at all; but again, once we get to the clinic, you won't know. The models for — the animal models for predicting hyperpigmentation, or — they aren't especially well validated. So we do know we run them. But I think overall, you have to rely on selectivity in your activity profile and then get into the clinic.

Analyst

analyst
#16

Okay. You also saw some early effect on blood pressure. So I'm just curious what further work you're considering to more firmly establish that cardiovascular profile.

Carl Spana

executive
#17

I mean, obviously the cardiovascular profile — cardiovascular safety matters for any drug, including this one. There are some legacy concerns about potential cardiovascular effects with MCR4s that our compound doesn't have. So we'll keep evaluating the impact on blood pressure and on rhythm all the way through the TOX program. That gets done in dedicated studies looking at blood pressure and tracings, and also in your overall 7-day, 28-day tox and the longer-term tox studies. So there's nothing unique here in terms of what you'd do for all — for any drug going through development; we'll make sure that when we head into the clinic, we do have the right methodologies in place for evaluating blood pressure, so that when we come out of the SAD/MAD studies, we expect a clean profile.

Dev Prasad

analyst
#18

Just a fast question about how things are going toward Phase I. Could you walk us through what still needs to happen between now and when the Phase I trial of the lead lipidated peptide begins?

Carl Spana

executive
#19

Absolutely. Much of the — think of the tox program as covering in vitro work, meaning non-animal studies, plus animal studies. Most of the neutral studies are finished; we're now preparing to kick off the 28-day study in rats as well as dogs, and honestly that's the key gating item — once it wraps and those reports come in, we'll be in a position to file. Alongside that, naturally, there are the continuing CMC requirements — stability and all the rest — and making sure the necessary documentation is ready for both the API, or the drug itself, and the drug product, and all of that remains on track to be in place so we can file in the second quarter of next year.

Dev Prasad

analyst
#20

Great. And could you discuss R&D expenses going forward, since it looks like you had a fairly substantial expense in the September quarter?

Carl Spana

executive
#21

I'll hand that to Steve.

Steve Wills

executive
#22

Alright, I’ll take this question. The rise in R&D spending is clearly tied directly to progress on our priority development programs — in particular, the IND-enabling work for our lead lipidated peptide, along with ongoing optimization of our small molecule and oral peptide candidates. We see this as a significant investment in moving our programs forward toward clinical development. As we get closer to launching the Phase I studies next year, some development costs will inevitably rise, especially those tied to manufacturing, toxicology, regulatory activities, and preparation for the clinical trial. That said, we retain substantial flexibility when it comes to managing how expenditures are timed and how quickly they are made. Our capital allocation strategy centers on the programs we think hold the greatest potential — which, clearly, are our MC4R programs — and that means putting priority on the lead long-acting peptide and oral MC4R programs while using partnerships to move the other assets ahead; we do believe this disciplined approach lets us focus our resources on the opportunities with the greatest potential to create shareholder value.

Yale Jen

analyst
#23

Carl, you mentioned that the live data peptide might be usable orally. Can you expand on that a bit more, and also — were there any instances of a drug already created from the liquidated peptide into oral — the oral...

Carl Spana

executive
#24

Certainly. The biggest one, clearly, is semaglutide, which of course was first developed as Ozempic. And < > and created as an oral formulation. So that's the Gobeil, — so till semaglutide simply formulated for oil delivery; and from where we sit, that's — one benefit of taking the lipidated peptide route is that it does unlock the ability to do that. Simple peptides tend to have fairly short half-lives. So even if the — even if they come already bioavailable, in the 5%, 6%, 7% range, they will get broken down fairly quickly. But when peptides are absorbed, they bind to albumin right away, so they are shielded and have a long half-life, so you can build up to a therapeutic dose gradually over roughly a week or so of dosing. So it's a well-validated approach now, given the GLP-1s. And a number of companies are pursuing this kind of approach. I mean, a big one being protagonist as being a big one that has plenty of oil peptide approaches and you can look at their portfolio and how they operate. But — one of the crucial things for these peptides is that not only that the ore they buy available, they truly must have prolonged half-lives once absorbed. Because these aren't absorbed at 70% or 80%. These are 3%, 4%, 5% core bioavailability. But since they're lipidated and they accumulate, you can reach a therapeutic dose or dose with them.

Yale Jen

analyst
#25

Quick side question, if I may. Are all the GLP-1s, or the GLP, given as sub Q1, or do they come in lipidated form? Or is that how it works?

Carl Spana

executive
#26

That's how I understand it. From what I understand, if they're peptides, they get lipidated. There are definitely small molecules, conventional oral small molecules such as the Lilly product that's approved; and quite a few smaller molecules are in development. But those haven't performed as well as — forgone hasn't come nearly as close as the go pill, in a sense, because it would be pieceamaglutide basically just given orally. So it's the identical peptide. So — but the majority of them, they have to be lipidated.

Yale Jen

analyst
#27

All right, thanks. I've got a question about the Phase I study that you plan to begin next year. Do you feel there's sufficient time for that study — and once you present its data, is it likely that hyperpigmentation will show up in patients, or that other biomarkers will indicate you could somewhat reduce it...

Carl Spana

executive
#28

With hyperpigmentation and MCR1, if it's going to happen you'll notice it after roughly the first one to two doses; the effect comes on very fast. When you're activating MC1R melanocytes, skin darkening appears pretty quickly, so a MAD study lasting 28 days is plenty to determine whether there's meaningful MC1R activity and high pigmentation.

Yale Jen

analyst
#29

So if that turns out to be true, there's a good chance the selectivity did what it was supposed to do with respect to < >

Carl Spana

executive
#30

If the 28-day study is looking at clearance of hyperpigmentation, then you won't have hyperpigmentation. — on that Milano side, the — your skin renews itself about once a month. So you won't notice anything. If you're referring to that study, you're clear.

Yale Jen

analyst
#31

Great, great. Perhaps one final question for Steve. We saw that during last year, Boehringer Ingelheim had somewhat uneven revenue — a bigger chunk of it came in. Do you think that kind of pattern could show up later this year, or in fiscal '27, I should say, and potentially reduce some of the requirement for larger financing or anything like that?

Steve Wills

executive
#32

Are you talking about the, let's say, the BI — the Boehringer Ingelheim funds that arrived over the last...

Yale Jen

analyst
#33

Yes.

Steve Wills

executive
#34

For reasons of competition and confidentiality, we aren't disclosing the expected milestones or their timing — what we can say is that we've received roughly $10 million from August of 2025 onward. The program keeps moving forward and is coming along nicely. It's a strong partnership. We're big fans of the BI team. My sense is they feel the same about the Palatin team. As we push the program ahead, more milestones will come.

Yale Jen

analyst
#35

All right. Wonderful. That's really useful. Once more, best of luck with every bit of the progress, I mean, you folks are certainly setting up what could be a gold mine, and hopefully you can begin harvesting later on.

Carl Spana

executive
#36

Thanks to all of you for joining our quarterly conference call. I appreciate the analysts and their insightful questions. And we truly are excited here. There's a lot going on, we've made tremendous progress, and we have a great team focused on delivering. So we're genuinely excited and look forward to continuing to update us on our success and our progress. So thank you, everyone. Have a great day, and we'll keep you folks updated as we make progress.

Operator

operator
#37

Thanks, everyone — that brings today's conference call to an end. At this point you're welcome to hang up your phone lines, and we hope the rest of your day is wonderful. We appreciate you joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.